NCT06161220已完成1 期
A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Change from baseline QTcF (ΔQTcF)
研究概览
简要总结
The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
Double blinded (for test and negative control) and open label (for active control)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males and females aged 18 to 55 years (both inclusive)
- •For female subjects of childbearing potential, use of double contraception method
- •Body Mass Index (BMI) 18.5 to <30 kg/m² at Screening, with a minimum weight of 55kg
- •Subject with no clinically significant abnormal serum biochemistry, hematology and urine examination values at screening
- •Subject with negative urine screen for drugs of abuse at screening
- •Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results at screening
- •Subject must be willing to communicate with the investigator and site staff and comply with all study procedures and requirements
- •Subject must be able to provide written, informed consent including compliance with the requirements listed in the consent form
- •Subject must be able and willing to swallow whole capsules without breaking, cutting, or chewing
排除标准
- •History or presence of systemic diseases at Screening, which as judged by the investigator, may affect the outcome of this study, include, but not limited to significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
- •Female subjects who are pregnant or lactating
- •Knowledge of any kind of cardiovascular disorder/condition known to increase the possibility of QT prolongation or history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome or Brugada Syndrome) or cardiac conduction disorders
- •Resting supine heart rate less than 50 beats per minute or greater than 100 beats per minute
- •Resting supine systolic blood pressure less than 90 mmHg or greater than 140 mmHg; resting supine diastolic blood pressure less than 50 mmHg or greater than 90 mmHg.
- •Clinically significant (as determined by the Investigator) ECG abnormalities at Screening, including:
- •QTcF > 450 ms for female and >430 ms for male
- •QRS > 110 ms
- •PR > 200 ms
- •QTcF > 450 ms for female and >430 for male
- •QRS > 110 ms
- •PR > 200 ms
- •Resting supine HR <50 beats per minute (bpm) or >100 bpm (may be repeated once at the discretion of the investigator)
- •Second or third-degree AV block
- •Any rhythm other than sinus rhythm, which is interpreted by the Investigator to be clinically significant
- •Bundle Branch Block
- •premature atrial and ventricular contractions,
- •nonspecific T-wave changes
- •Positive urine/serum drug screen at Screening or Day -1 for each Period
- •History of significant alcohol abuse or drug abuse within one year prior to Screening.
- •Use of prescription medication (with the exception of medically approved hormonal contraceptives) including MAO inhibitors in the 30 days prior to admission into Period 1 and over-the-counter medications including vaccines, vitamins, and herbal remedies within 14 days prior to admission of Period 1 till completion of the study (EOS or ET)
- •History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations or near drowning with hospital admission
- •Subjects who received any investigational drug within the longer of 30 days or 5 half-lives of Day 1 dosing of SM
- •Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study
- •Use of medications in the 90 days before admission of the study that are known to prolong the QT/QTc interval.
- •Family history of QTc prolongation or of unexplainable sudden death at <50 years of age. For this study, family is defined as 1st degree relative (i.e., mother, father, siblings, children) or 2nd degree relative (grandparents, grandchildren, half-siblings, aunt/uncle, niece/nephew).
- •Subjects who cannot refrain from using tobacco of any kind within 30 days prior to admission (Day -1) of Period 1 until the last blood sample collection of study
- •Subjects who cannot refrain from consumption of alcohol or alcohol containing products or xanthine-containing foods or beverages (like chocolate, tea, coffee or cola drinks) within 48 hours prior to admission (Day -1) of Period 1 till the last blood sample collection of study
- •Subjects who participate in other drug research study during the study.
- •Subjects who cannot refrain from donating blood or plasma for 30 days and 14 days (respectively) prior to dosing, during the study, and for at least 4 weeks after completing the study.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Moxifloxacin Tablets, USP (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Carbidopa capsule
Experimental
Dose: 4x 100 mg
干预措施: Carbidopa capsule (Drug)
Carbidopa capsule
Experimental
Dose: 4x 100 mg
干预措施: Moxifloxacin Tablets, USP (Drug)
Carbidopa capsule
Experimental
Dose: 4x 100 mg
干预措施: Placebo (Drug)
Moxifloxacin Tablets, USP
Active Comparator
Dose: 400 mg
干预措施: Carbidopa capsule (Drug)
Moxifloxacin Tablets, USP
Active Comparator
Dose: 400 mg
干预措施: Moxifloxacin Tablets, USP (Drug)
Moxifloxacin Tablets, USP
Active Comparator
Dose: 400 mg
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
干预措施: Carbidopa capsule (Drug)
结局指标
主要结局
Change from baseline QTcF (ΔQTcF)
时间窗: Predose to 24 hours postdose
Change-from-baseline QTcF ( QTcF) will allow evaluation of the effects of carbidopa and moxifloxacin on cardiac repolarization based on model derived placebo-corrected ΔQTcF (ΔΔQTcF).
次要结局
- Change from baseline HR, PR, and QRS(Predose to 24 hours postdose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy VolunteersHealthyNCT00415922Novartis42
已完成
2 期
High and Low Dose Carbidopa Treatment of Parkinson's DiseaseParkinson's DiseaseNCT01399905Oregon Health and Science University14
终止
4 期
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing OffParkinson's DiseaseNCT00642356Novartis14
已完成
2 期
An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)Parkinson's DiseaseNCT00200447Molecular NeuroImaging3
已完成
1 期
Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female VolunteersAcinetobacter Baumannii-calcoaceticus Complex InfectionsNCT03985410Entasis Therapeutics32